pathophysiology, management and outcome of persistent pulmonary hypertension of the newborn: a clinical review
Clicks: 250
ID: 249261
2013
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Popular Article
30.0
/100
250 views
59 readers
AI Quality Assessment
Not analyzed
Readership in this journal
PopularRanked #57 of 90 articles by views in disease markers
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Persistent Pulmonary Hypertension of Newborn (PPHN) results from the failure of relaxation of the pulmonary vasculature at birth, leading to shunting of non oxygenated blood from the pulmonary to the systemic circulation. More often, full term and near term infants are affected, however it is not uncommon to see PPHN in preterm infants who have respiratory distress syndrome. In some infants pulmonary vascular remodeling is present at birth, pointing towards the prenatal onset of the disease process. Regardless of the etiology, PPHN should be diagnosed and treated as soon as possible to avoid hypoxia related short term and long term morbidities. The mainstay therapy is the treatment of the underlying condition along with several promising therapeutic modalities such as oxygen supplementation, mechanical ventilation, Nitric Oxide, Phospho-diesterase inhibitors, prostaglandins analogues, endothelin receptor antagonists, and extracorporeal membrane oxygenation. The optimal approach to the management of PPHN remains controversial. After discharge from the NICU, infants with PPHN warrant long term follow up since they are at risk for neurodevelopmental disabilities and chronic health conditions.
| Reference Key |
mhanna2013frontierspathophysiology,
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Maroun Jean Mhanna;Mohammed Ashraf Puthiyachirakkal |
| Journal | disease markers |
| Year | 2013 |
| DOI |
10.3389/fped.2013.00023
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.